reason report
bottom line lower price target
updat merck guidanc given impact human
anim health busi merck impress us report
oper chang employ mitig risk
clinic trial believ may translat small mid-term
sale despit risk convey call six-week dose
keytruda fda approv yesterday add keytruda advantag
tried-and-tru option patient treat
pandem reliev merck put full strength
vaccin organ task given advantag
see larg experienc vaccin manufactur clinic trial
execut regulatori manufactur merck take broad
tradit approach vaccin develop base
on-going preclin immun correl work
though roger perlmutt suggest merck seen clearli
posit signal anti-tigit recent strateg move suggest
aggress posit discuss anti-tigit came
 set analyst question suggest threat roch
rhhbi cover anti-tigit tiragolumab nsclc merck
dismiss threat note promis keytruda combin
lenvima lenvatinib addit twenti promis biolog merck
put forward aggress strateg postur clinicaltri gov
first gave anti-tigit name vibostolimab
second post three new trial vibostolimab keytruda
melanoma includ triplet combin
top decemb start trial test
triplet vibostolimab keytruda chemotherapi non-smal cell
lung cancer nsclc third dose escal trial new
cohort aim directli keytruda life-cycl manag fixed-dos
co-formul product vibostolimab pembrolizumab
roch move sever registration-en trial
tiragolumab view merck competit posit compani
start larg trial provid tremend amount cohort
expans biomark data inform strategi tabl
summari roch merck anti-tigit trial appendix tabl
full list keytruda catalyst
dcf use wacc
account net cash
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu present ep
pleas refer page import disclosur price chart analyst certif
reliev merck put full strength vaccin organ
task merck manag remind us author vaccin
histori stellar modern accomplishmentsdevelop four seven vaccin
previous unaddress human pathogen last year much agre
timelin scale requir put larg experienc vaccin compani
lead posit even assum vaccin perform similarli believ rapidli
execut high-qual global efficaci studi negoti regul tricki topic like
relev immun correl scale million dose requir
consider skill experi recent note challeng uncertainti
merck take vaccin develop approach learn colleg
minut prepar save hour lab begin develop
comprehens understand well character immun correl
collabor sever academ center plan develop vaccin
use proven platform mrna merck manag much like colleagu
geoff porg link believ safeti record proven platform posit better
meet high safeti bar potenti vaccin entir global popul also seem
suggest respons question mrna might stimulatori enough least
singl vaccin final share commit openli share data collabor
wide fight diseas
hurt larg physician-administ portfolio strong dollar exposur anim
health merck lower annual revenu guidanc
non-gaap ep announc paus share-
buyback much impact come merck manag believ healthcar
util volum recov inform evolut china expect
go earn link seen rapid drop bridion sale due non-elect
urgent surgeri though see demand increas pneumovax overal vaccin
portfolio neg impact patient physician delay well-visit fertil
women health implant also impact physician administ tabl
updat project major product product class impact covid-
believ keytruda sale may remain strong despit risk convey
call maintain ionian-simul project pre-covid
continu quit accur forecast vs actual sale
merck manag said believ oncolog resili see new patient visit
declin treatment barrier clear headwind downsid
everi month lost keytruda sale growth believ keytruda could benefit competit
clinical-car paus upsid ask impact clinic care
medacorp kol express desir stick standard-of-car therapi express
skeptic new launch could success without in-person tumor board coffe
interact physician inform share experi new therapi halt in-
person sale forc interact dampen buzz virtual congress present could
slow awar commun overal believ disrupt could posit
keytruda tried-and-tru option may especi true non-smal cell lung
cancer nsclc cover roch cover may struggl launch
opdivo nivolumab yervoy ipilimumab /- chemo pdufa date may august
like data virtual tecentriq pdufa june respect appli
three-month delay launch industry-wid result increas keytruda sale rel
previou base case next three year figur
believ six-week dose keytruda mg add keytruda advantag
tried-and-tru option patient treat pandem merck
announc fda approv regimen yesterday ad offici bless
present six-week data melanoma regimen got call-out dr paolo
ascierto aacr present experi use oncolog drug patient
prefer schedul dr ascierto also note may actual may prevent sever
diseas could increas viral clearancea hypothesi current test
nivolumab clinic
merck report effect oper chang mitig risk
clinic trial still assum three-month delay oncolog trial figur merck
halt enrol initi new trial site manag databas lock
remot lock march illustr top-notch remot monitor site interact
capabl report expect oper effici includ save
clinic trial spend indic see delay effort moder
extent mid-term impact may give merck advantag assum competitor abl
meet high oper bar
tabl on-going merck roch anti-tigit clinic cohort
umbrella trial end-dat seem reflect overal trial end rather individu rotat cohort end-dat
figur risk disrupt annual us sale select antagonist
svb leerink ionian immuno-oncolog industri analyt base median revenu iter
simul assum disrupt diagnosi sale product current approv set
tabl bridion revenu estim million world-wide
tabl pneumovax revenu estim million world-wide
tabl gardasil revenu estim million world-wide
tabl women health revenu estim million world-wide
appendix tabl major catalyst antagonist
event link relev
data
data kestrel
data
data
data javelin lung
lenvatinib keytruda
data opdivo yervoy
data himalaya
imfinzi w/
appendix tabl major catalyst program outsid io
readout adult
compani report inform purpl shade competitor program
heart failur
sourc svb leerink estim compani report financi
mrk fortun tie keytruda sale trial readout
primari driver share price
mrk earli all-in bet solid clinic commerci execut establish deep
believ investor underappreci potenti
long-term divers keytruda revenu come expans earlier
line addit tumor type price increas
return mrk aggress strategi explor collabor
pursu partnership acquisit promis keytruda add-on approach
extend keytruda competit moat life-cycle beyond patent-lif
flip side believ investor overli worri price
disrupt view exceedingli unlik event given keytruda
expect continu growth vaccin gardasil pediatr vaccin long-term
prospect stabl given high barrier brand gener entri
mrk pipelin asset see potenti disrupt islatravir hiv
extend dose prep vericiguat add-on therapi high-risk decompens
heart failur well opportun show industry-lead
market-shap gefapix chronic cough
price target base dcf analysi use wacc
account net cash assum valu organon spin-out project revenu
gener rang outcom keytruda mrk io asset deriv
mont carlo simul entir io industri pipelin develop path
iter model growth vaccin hiv franchis consensu estim
vertic
keytruda-specif risk increment scientif innov io may continu prove
difficult initi burst fail pursu most-promis add-on
therapi bd competitor reli deeper intern pipelin
price reimburs relat risk us legisl affect drug price propos
price model risk commerci pharma keytruda exposur
medicar part could make particularli sensit us health-system reform
oncolog model remov practic incent prefer high-volum high-reb option
major leg keytruda competit moat risk reimburs enhanc oversea
re-negoti drug switch routin practic low-cost local altern
china could drive price one keytruda fastest grow market
also face execut risk plan spin-out low-margin asset organon disrupt
accret assum
